SureTrader SPDR Advertisement
Home > Boards > US Listed > Biotechs >

Mast Therapeutics, Inc. (MSTX)

MSTX RSS Feed
Add MSTX Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator BooDog, Rhodey Red
Search This Board:
Last Post: 7/29/2015 1:38:31 PM - Followers: 313 - Board type: Free - Posts Today: 2

Mast Therapeutics
 We are a publicly traded biopharmaceutical company headquartered in San Diego, California.

We are leveraging the MAST (Molecular Adhesion and Sealant Technology) platform, derived from over two decades of clinical, nonclinical and manufacturing experience with purified and non-purified poloxamers, to develop MST-188, our lead product candidate, for serious or life-threatening diseases with significant unmet needs.


http://wsw.com/webcast/cowen16/MSTX/  Webcast from Cowen Healthcare Conference 03/03/14

http://www.masttherapeutics.com/wp-content/uploads/2012/09/MastThera_CorpPres_07.09.2013.pdf


http://www.media-server.com/m/p/to9vgb8uhttp://www.media-server.com/m/p/to9vgb8u  Piper Jaffray Healthcare Conference 12/03/13 : 30 minute audio presentation by CEO B. Culley  NEW

http://www.masttherapeutics.com/wp-content/uploads/2012/09/MastThera_CorpPres_10.08.2013.pdf    12th Annual Bio-Investor Conference 10/08/13: 32 page PDF NEW

http://www.masttherapeutics.com/company/ceo-blog/ 
Blog Update from CEO B. Culley 12/12/13  NEW

http://www.masttherapeutics.com/investors/news/?releaseid=1887966  Data From Proof of Concept Study in Heart Failure 
01/06/13


2015 Biotech Conference Presentation Slides: January 12th 2015.  http://www.sec.gov/Archives/edgar/data/1160308/000119312515007330/d850231dex991.htm


ClinicalTrials.gov

 
A service of the U.S. National Institutes of Health

 

  • Make bi

 

Evaluation of Purified Poloxamer 188 in Children in Crisis (EPIC)

This study is currently recruiting participants.
Verified July 2013 by Mast Therapeutics, Inc.
Sponsor:
Mast Therapeutics, Inc.
Information provided by (Responsible Party):
Mast Therapeutics, Inc.
ClinicalTrials.gov Identifier:
NCT01737814
First received: November 27, 2012
Last updated: July 22, 2013
Last verified: July 2013

The purpose of this study is to evaluate whether ANX-188 can reduce the duration of vaso-occlusive crisis (VOC) in subjects with sickle cell disease. The study will also evaluate whether ANX-188 can reduce the frequency of rehospitalization of subjects due to a recurrence of VOC. Additionally, this study will compare the development of acute chest syndrome during VOC in subjects who receive ANX-188 to those who do not receive ANX-188.


Condition Intervention Phase
Vaso-occlusive Crisis
Sickle Cell Disease
Drug: ANX-188
Drug: Saline
Phase 3
 
Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
Official Title: Evaluation of Purified Poloxamer 188 in Children in Crisis (EPIC): A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial of ANX-188 (Purified Poloxamer 188) Injection in Children With Sickle Cell Disease Experiencing Vaso Occlusive Crisis
Resource links provided by NLM:
 
Further study details as provided by Mast Therapeutics, Inc.:
 
Primary Outcome Measures:
  • Reduction of the duration of vaso occlusive crisis (VOC) in subjects with sickle cell disease. [ Time Frame: Study participants will be followed for the duration of hospital stay, an expected average of 4 days ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Re-hospitalization rate for VOC [ Time Frame: Hospital discharge to 14 days post-discharge ] [ Designated as safety issue: No ]
    Occurence of acute chest syndrome [ Time Frame: Randomization to 120 hours after randomization ] [ Designated as safety issue: No ]
 
Estimated Enrollment: 388
Study Start Date: May 2013
Estimated Primary Completion Date: December 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: ANX-188
ANX-188 injection administered as a continuous infusion 100 mg/kg for 1 hour followed by 30 mg/kg/hr for up to 48 hours.
Drug: ANX-188
Placebo Comparator: Saline
Saline administered as a continuous infusion for up to 49 hours
Drug: Saline

 

 
Please refer to this study by its ClinicalTrials.gov identifier: NCT01737814

Contacts
Contact: Mast Therapeutics CT.gov Call Center 1-888-965-1238  

 
Responsible Party: Mast Therapeutics, Inc.
ClinicalTrials.gov Identifier: NCT01737814     History of Changes
Other Study ID Numbers: ANX-188-01
Study First Received: November 27, 2012
Last Updated: July 22, 2013
Health Authority: United States: Food and Drug Administration

Keywords provided by Mast Therapeutics, Inc.:
sickle cell disease
vaso-occlusive crisis

Additional relevant MeSH terms:
Anemia, Sickle Cell
Anemia, Hemolytic, Congenital
Anemia, Hemolytic
Anemia
Hematologic Diseases
Hemoglobinopathies
Genetic Diseases, Inborn

ClinicalTrials.gov processed this record on July 25, 2013

 

Technology

 

Hematology

MST-188 (lead product candidate)

MST-188 (purified poloxamer 188) is an investigational agent that has potential to reduce ischemic tissue injury and end-organ damage by restoring microvascular function, which is compromised in a wide range of serious and life-threatening diseases and conditions. We initially are developing MST-188 as a treatment for complications arising from sickle cell disease.

 

2013 Activities

Event Timing

Initiate tQT/QTc Study Completed

Secure Orphan Designation for MST-188 for SCD in EU Completed

Activate First Site in Phase 3 Study Completed

File New Patent Applications Completed

Dose First Subject in Phase 3 Study Completed

Report data from tQT/QTc Study Q3 Completed and Primary Endpoints Met

Request Orphan Designation for MST-188 for ALI in U.S. Q3 Completed and Designation Granted By FDA

Initiate Nonclinical Proof-of-Concept Study in Heart Failure Q3 Completed and POC Data to be released Q1 '14

2014 Activities

Event Timing


Present Data From Nonclinical Proof-of-Concept Study In Heart Failure  Q1 '14  Data Released 01/06/14'Showed Significant Statistical Improvement"

Initiate Phase 2 Study in ALI Q1 '14 Initiated

Outcome of review of application for Unique Name Designation For Purified Poloxamer 188 From U.S. Adopted Names Counsel Q1 '14 Granted and Named VEPOLOXAMER

Open First Ex-U.S. Clinical Sites in Phase 3 Trial Q1 '14. Initiated and On Schedule

Submit Abstract with Heart Failure Study Biomarker Data to Major Medical Conference Q2 '14

Request Orphan Designation for ALI in EU Q2 '14  Application Submitted

Initiate Nonclinical POC Study in Stroke Q2 '14 Study Initiated

Initiate EPIC Sub-Study Q2 '14 Initiated On Schedule 06/14/14

Report Results from Phase 2 Study of AIR001 in PAH Q3 '14 Positive Top line Data released 9/8/14

Initiate study with Dept of Defense: MST-188 Resuscitation from major trauma '14 CRADA with US Military Initiated Q3 '14

Receive protocol from FDA for Phase 2 Heart Failure Study Q4'14 FDA Approves Heart Failure Study 12/9/14

2015 Event Schedule

Initiate dosing Phase2a study in AIR001 Q1 '15.  INITIATED 2/4/15

Nonclinical Study EMBOLIC STROKE Data Q1 '15:  POSITIVE DATA RELEASED 2/11/15

Report nonclinical data for repeat dose on Vepoloxamer in Heart Failure Q1 '15 POSITIVE DATA RELEASE 03/02/15

Phase 2 Study HEART FAILURE Initiate Enrollment Q2 '15 INITIATED 3/23/15

EPIC EXTENSION STUDY (Repeat Exposure) Initiate Enrollment 1st Half '15 INITIATED 5/26/15 

Phase 2a Study of AIR001 (WHO GROUP 2) in HFpEF Preliminary Data 2nd Half '15

Phase 2 Study Heart Failure Interim Safety Analysis 2nd Half '15

EPIC STUDY COMPLETE ENROLLMENT Q4 '15

2016 EVENTS

EPIC STUDY TOP LINE DATA Q1 '16

Phase 2 Study Acute Limb Ischemia COMPLETE ENROLLMENT 2nd Half '16







 

Video of Management of Mast Therapeutics $MSTX speaking about MST-188 for Sickle Cell Disease ,orphan drug 
http://www.youtube.com/watch?v=eI7inPOiyZM&feature=youtu.be 
http://www.masttherapeutics.com/wp-content/uploads/2013/04/EPIC-An-Ongoing-Pivotal-Phase-3-Study-in-Patients-with-Sickle-Cell-Disease-Aug-21-2013.




 

Schedule 13D and 13G filings submitted since 09/30/14

  Filing Company Date of
Filing
Total Reported
Shares Owned
Shares Reported
on 13F
  Baker Bros LLC 12/31/14 4,774,434 4,774,434
  BVF Inc. 3/31/15 7,241,600 7,241,600!
SC 13G FRANKLIN RESOURCES INC 02/04/15 11,946,100 11,946,100
Reported via Event Date Name Ticker Shares * Change % of Portfolio
13F MPM Asset Management     MSTX 2,551,851    
13F Vanguard Group     MSTX 3,382,483    
13F Proquest Associates                                                                                                                                                                                                      MSTX.                        2,551,851



 

                                                                       






http://stockcharts.com/h-sc/ui?s=MSTX&p=D&b=2&g=0&id=p32395513381

http://stockcharts.com/h-sc/ui?s=MSTX&p=D&b=9&g=0&id=p36778398928

http://stockcharts.com/freecharts/gallery.html?MSTX

                                                       

Contact Information

P: 858-552-0866    F: 858-552-0876
General Inquiries
info@mastthera.com

Investor Relations Contact
ir@mastthera.com

Business Development Contact
busdev@mastthera.com

Careers Contact
hr@mastthera.com

 

                                                                                                 

                                                                                                                                                 

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
MSTX
Current Price
Volume:
Bid Ask Day's Range
Wiki
MSTX News: Current Report Filing (8-k) 07/21/2015 07:31:55 AM
MSTX News: Current Report Filing (8-k) 06/25/2015 08:02:07 AM
MSTX News: Current Report Filing (8-k) 06/16/2015 04:11:56 PM
MSTX News: Statement of Changes in Beneficial Ownership (4) 06/12/2015 05:45:46 PM
MSTX News: Statement of Changes in Beneficial Ownership (4) 06/12/2015 05:19:06 PM
PostSubject
#12977   This is not good here!Sell my shares 2 harmsen 07/29/15 01:38:31 PM
#12976   Wow add to the disappointment stocks up 300 pray 07/29/15 11:59:49 AM
#12975   Simple ...... pray 07/28/15 12:06:43 AM
#12974   Mast Therapeutics: Why Is The Stock Lagging Despite Woulfe 07/24/15 10:53:42 AM
#12973   Pray, it's very simple...for my current investment strategy Rhodey Red 07/22/15 07:33:10 AM
#12972   Why call it the finish when test are pray 07/22/15 06:52:40 AM
#12971   Thanks Pray. I'm always here, but with the Rhodey Red 07/22/15 06:22:47 AM
#12970   Ps great to have ya back. Had not pray 07/21/15 11:51:49 PM
#12969   The sole purpose of the PR was to pray 07/21/15 09:32:46 PM
#12968   For clarity Pray, today's 8k filing wasn't news. Rhodey Red 07/21/15 07:35:33 PM
#12967   No uptick even on news. CEO destroyed this pray 07/21/15 09:45:21 AM
#12966   Tee times cancelled for today .... must be pray 07/21/15 09:22:53 AM
#12965   $MSTX 7/21 Slide presentation, EPIC SCD ph 3 Blinkx90 07/21/15 08:11:13 AM
#12964   Might as well buy a few more at pray 07/16/15 10:55:15 AM
#12963   Battle of the moving averages 200dma and then BooDog 07/14/15 08:32:02 PM
#12962   Of course a $2-$3mln commitment for them is Blinkx90 07/11/15 06:44:54 AM
#12961   Looking VERY good here, fundamentals continue to improve BooDog 07/10/15 10:51:24 PM
#12960   To be fair, 4.7m shares at their base okaly 07/10/15 07:58:39 PM
#12959   "We'll know if Mast is right in about Blinkx90 07/10/15 01:54:38 PM
#12958   Baker Bros doesn't own 4.7m shares of $MSTX Blinkx90 07/10/15 11:59:24 AM
#12957   Lol seems like it! TheProfitPope 07/10/15 01:24:46 AM
#12956   Okaly, clearly "never" isn't an accurate answer to Rhodey Red 07/10/15 01:03:41 AM
#12955   Never. okaly 07/10/15 12:04:40 AM
#12954   When will data be out ?? TheProfitPope 07/09/15 08:46:32 PM
#12953   If you go back over the last couple pray 07/09/15 08:18:57 PM
#12952   Apple trading at .02 spread is a lot okaly 07/09/15 06:05:26 PM
#12951   You're not understanding, in that scenario, it DOESN'T Blinkx90 07/09/15 06:02:50 PM
#12950   But you're not understanding what im saying. okaly 07/09/15 05:53:22 PM
#12949   Trust me, yes there is. Blinkx90 07/09/15 05:49:51 PM
#12948   Yes of course many stocks have legit "late" Blinkx90 07/09/15 05:42:13 PM
#12947   And second, the orders print as the market okaly 07/09/15 05:30:20 PM
#12946   I see several stocks print orders at 4:01 okaly 07/09/15 05:28:25 PM
#12945   Sorry, I have been trading for over 20 Blinkx90 07/09/15 05:26:34 PM
#12944   If you think that someone is responsible for okaly 07/09/15 05:02:05 PM
#12943   Yes, 100% owned for now. I'm actually happy Rhodey Red 07/09/15 03:16:32 PM
#12942   Right, just pointing out the potentially huge market Blinkx90 07/09/15 01:43:37 PM
#12941   All in favor of more players involved in Rhodey Red 07/09/15 01:06:04 PM
#12940   Global Blood Therapeutics files for a $115m IPO, Blinkx90 07/09/15 11:40:24 AM
#12939   What is the purpose to all that "painting"? Woulfe 07/09/15 09:27:20 AM
#12938   The painting everyday for months is amazing, first Blinkx90 07/09/15 08:43:50 AM
#12937   Ups ..... posted to fast after close. In pray 07/08/15 04:38:57 PM
#12936   Interesting ... In the green. Okay I was pray 07/08/15 04:23:35 PM
#12935   Yea .... even up a cent. See what pray 07/08/15 03:04:51 PM
#12934   Nothing beats a good shorty battle. See it's BooDog 07/08/15 01:15:48 PM
#12933   Really do not think MSTX is a "scam." pray 07/08/15 12:47:43 PM
#12932   Good starting point below for those who can Blinkx90 07/08/15 07:53:17 AM
#12931   Expecting an EPIC is 75% enrolled PR soon, Blinkx90 07/08/15 07:24:35 AM
#12930   Watching a small bio move forward can be BooDog 07/08/15 06:44:28 AM
#12929   Glad you touched on the biggest problem here. okaly 07/07/15 07:21:37 PM
#12928   You are correct but most bio-techs that move pray 07/07/15 01:36:04 PM
PostSubject